Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

AstraZeneca AZN recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. The announcement comes just days after Pfizer PFE signed a similar deal ...

Over the past decade, AstraZenecaAZN has built a broad oncology franchise spanning multiple cancer types, including lung, ...

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...

When seven biopharma executives were asked by senators in February whether they had intentionally blocked generic competition, all of them said no. But several of the companies’ products were included ...